Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Abstract 6406: Radiation and STING activation limit tumor development and modulate the immune environment via distinct mechanisms

Kay Shigemori, Yanyan Jiang, Bruno Beernaert, Anderson J. Ryan, Eileen E. Parkes

Cancer Res (2023) 83 (7_Supplement): 6406.

https://doi.org/10.1158/1538-7445.AM2023-6406

Published: 04 April 2023

View articletitled, Abstract 6406: Radiation and STING activation limit tumor development and modulate the immune environment via distinct mechanisms

Journal Articles

Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Guillaume Rieunier, Xiaoning Wu, Letitia E. Harris, Jack V. Mills, Ashwin Nandakumar, Laura Colling, Elena Seraia, Stephanie B. Hatch, Daniel V. Ebner, Lisa K. Folkes, Ulrike Weyer-Czernilofsky, Thomas Bogenrieder, Anderson J. Ryan, Valentine M. Macaulay

Cancer Res (2021) 81 (8): 2128–2141.

https://doi.org/10.1158/0008-5472.CAN-20-2860

Published: 15 April 2021

View articletitled, Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Includes: Supplementary data

Journal Articles

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

Cancer Res (2021) 81 (7): 1667–1680.

https://doi.org/10.1158/0008-5472.CAN-20-0177

Published: 01 April 2021

View articletitled, Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

Includes: Supplementary data

Journal Articles

Abstract 3785: Olaparib increases the effectiveness of radiation in hypoxic tumor cells in xenograft models of human non-small-cell lung cancer

Yanyan Jiang, Tom Verbiest, Aoife M. Devery, Sivan M. Bokobza, Anika M. Weber, Anderson J. Ryan

Cancer Res (2014) 74 (19_Supplement): 3785.

https://doi.org/10.1158/1538-7445.AM2014-3785

Published: 01 October 2014

View articletitled, Abstract 3785: Olaparib increases the effectiveness of radiation in hypoxic tumor cells in xenograft models of human non-small-cell lung cancer

Journal Articles

Abstract 5254: Cedarinib inhibits VEGF-stimulated proliferation in NSCLC cell lines.

Aoife M. Devery, Rekha Wadeka, Sivan M. Bokobza, Anika M. Weber, Yanyan Jiang, Anderson J. Ryan

Cancer Res (2013) 73 (8_Supplement): 5254.

https://doi.org/10.1158/1538-7445.AM2013-5254

Published: 15 April 2013

View articletitled, Abstract 5254: Cedarinib inhibits VEGF-stimulated proliferation in NSCLC cell lines.

Journal Articles

Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer models

Osamu Takahashi, Ritsuko Komaki, Paul D. Smith, Julian M. Jürgensmeier, Anderson J. Ryan, Benjamin N. Bekele, Ignacio I. Wistuba, Jörg J. Jacoby, Maria V. Korshunova, Anna Biernacka, Baruch Erez, Keiko Hosho, Roy S. Herbst, Michael S. O'Reilly

Cancer Res (2011) 71 (8_Supplement): 629.

https://doi.org/10.1158/1538-7445.AM2011-629

Published: 15 April 2011

View articletitled, Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer models

Journal Articles

Abstract 3279: Effects of the isoforms of the angiogenic growth factor VEGF on neo-vascularization and tumor response to the tyrosine kinase inhibitor cediranib

Rachel A. Daniel, Matthew Fisher, Miriam V. Flores-Merino, Giuseppe Battaglia, Anderson J. Ryan, David C. Blakey, Gillian M. Tozer

Cancer Res (2011) 71 (8_Supplement): 3279.

https://doi.org/10.1158/1538-7445.AM2011-3279

Published: 15 April 2011

View articletitled, Abstract 3279: Effects of the isoforms of the angiogenic growth factor VEGF on neo-vascularization and tumor response to the tyrosine kinase inhibitor cediranib

Journal Articles

Human cancer cell lines resistant to EGFR inhibitors acquire an altered expression of VEGFR-1/Flt-1 and become sensitive to ZD6474

Roberto Bianco, Gennaro Daniele, Terese Gelardi, Concetta Tuccillo, Anderson J. Ryan, A. Raffaele Bianco, Sabino De Placido, Fortunato Ciardiello, Giampaolo Tortora

Cancer Res (2006) 66 (8_Supplement): 888.

Published: 15 April 2006

View articletitled, Human cancer cell lines resistant to EGFR inhibitors acquire an altered expression of VEGFR-1/Flt-1 and become sensitive to ZD6474

Journal Articles

Tumor overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126

Elizabeth R. Cullis, Tammy L. Kalber, Susan E. Ashton, John R. Griffiths, Anderson J. Ryan, Simon P. Robinson

Cancer Res (2005) 65 (9_Supplement): 1376.

Published: 01 May 2005

View articletitled, Tumor overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126

Journal Articles

Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474

Alexandra Briggs, Danielle Molofsky, Andrew Wang, Jeffrey Engelman, Paul Beaudry, Daniela Prox, Sean Tracy, Anderson J. Ryan, Judah Folkman, Pasi Janne, Bruce E. Johnson, John V. Heymach

Cancer Res (2005) 65 (9_Supplement): 1372–1373.

Published: 01 May 2005

View articletitled, Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474

Journal Articles

Response of murine liver metastasis to the vascular-disrupting agent ZD6126 assessed by susceptibility MRI

Tammy L. Kalber, John R. Griffiths, John C. Waterton, Anderson J. Ryan, Simon P. Robinson

Cancer Res (2005) 65 (9_Supplement): 894.

Published: 01 May 2005

View articletitled, Response of murine liver metastasis to the vascular-disrupting agent ZD6126 assessed by susceptibility MRI

Journal Articles

Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer

Keiko Shibuya, Ritsuko Komaki, Tomoaki Shintani, Wenjuan Wu, Satoshi Itasaka, Takeshi Isobe, Anderson J. Ryan, Roy S. Herbst, Michael S. O’Reilly

Cancer Res (2005) 65 (9_Supplement): 1371.

Published: 01 May 2005

View articletitled, Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer

Journal Articles

AZD2171, an orally active inhibitor of VEGFR tyrosine kinase activity, reduces polyp burden in a mouse model of intestinal cancer

Robert Goodlad, A. James Watkins, Richard Poulsom, Anderson J. Ryan, Stephen R. Wedge, Ian T. Pyrah, Nikki Mandir, Robert W. Wilkinson

Cancer Res (2005) 65 (9_Supplement): 1374.

Published: 01 May 2005

View articletitled, AZD2171, an orally active inhibitor of VEGFR tyrosine kinase activity, reduces polyp burden in a mouse model of intestinal cancer

Journal Articles

ZD6474 inhibits human lung cancer bone metastases in a murine model by targeting both the tumor and its vasculature

Tomoaki Shintani, Valerae O. Lewis, Ritsuko Komaki, Wenjuan Wu, Anderson J. Ryan, Roy S. Herbst, Michael S. O’Reilly

Cancer Res (2005) 65 (9_Supplement): 1375.

Published: 01 May 2005

View articletitled, ZD6474 inhibits human lung cancer bone metastases in a murine model by targeting both the tumor and its vasculature

Journal Articles

Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells

Donata Vitagliano, Francesca Carlomagno, Maria Letizia Motti, Giuseppe Viglietto, Yuri E. Nikiforov, Marina N. Nikiforova, Jerome M. Hershman, Anderson J. Ryan, Alfredo Fusco, Rosa Marina Melillo, Massimo Santoro

Cancer Res (2004) 64 (11): 3823–3829.

https://doi.org/10.1158/0008-5472.CAN-03-3918

Published: 01 June 2004

View articletitled, Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells

Journal Articles

Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma

Joachim Drevs, Norbert Esser, Stephen R. Wedge, Anderson J. Ryan, Donald J. Ogilvie, Dieter Marme

Cancer Res (2004) 64 (7_Supplement): 1051–1052.

Published: 01 April 2004

View articletitled, Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma

Journal Articles

The VEGF receptor tyrosine kinase inhibitor ZD6474 significantly reduces intestinal tumor burden in the Min mouse

Robert W. Wilkinson, Anderson J. Ryan, Stephen R. Wedge, Ian T. Pyrah, Nikki Mandir, Robert A. Goodlad

Cancer Res (2004) 64 (7_Supplement): 1075.

Published: 01 April 2004

View articletitled, The VEGF receptor tyrosine kinase inhibitor ZD6474 significantly reduces intestinal tumor burden in the Min mouse

Journal Articles

Resistance of U87 glioblastoma to the vascular targeting agent, ZD6126: Reversal of resistance by NOS inhibitor, L-NNA

Phyllis R. Wachsberger, Randy Burd, Nichol Marrero, Peter A. McCue, Anderson J. Ryan, Adam P. Dicker

Cancer Res (2004) 64 (7_Supplement): 1250.

Published: 01 April 2004

View articletitled, Resistance of U87 glioblastoma to the vascular targeting agent, ZD6126: Reversal of resistance by NOS inhibitor, L-NNA

Journal Articles

Effect of cytotoxic antineoplastic drugs on endothelial cell response in vitro to the vascular-targeting agent ZD6126

Giulia Taraboletti, Gianluca Micheletti, Romina Dossi, Patrizia Borsotti, Michele Martinelli, Mariarosa Bani, Anderson J. Ryan, Raffaella Giavazzi

Cancer Res (2004) 64 (7_Supplement): 1252.

Published: 01 April 2004

View articletitled, Effect of cytotoxic antineoplastic drugs on endothelial cell response in vitro to the vascular-targeting agent ZD6126

Journal Articles

ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases

Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora, Giancarlo Vecchio, Anderson J. Ryan, Gabriella Fontanini, Alfredo Fusco, Massimo Santoro

Cancer Res (2002) 62 (24): 7284–7290.

Published: 15 December 2002

View articletitled, ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases

Update search

NARROW

Format

Journal

Article Type

Issue Section

Date

Availability

Abstract 6406: Radiation and STING activation limit tumor development and modulate the immune environment via distinct mechanisms

Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

Abstract 3785: Olaparib increases the effectiveness of radiation in hypoxic tumor cells in xenograft models of human non-small-cell lung cancer

Abstract 5254: Cedarinib inhibits VEGF-stimulated proliferation in NSCLC cell lines.

Abstract 629: MEK inhibition by selumetinib (AZD6244) inhibits progression with a multicentric antiangiogenic effect and enhances the efficacy of cediranib in orthotopic human lung cancer models

Abstract 3279: Effects of the isoforms of the angiogenic growth factor VEGF on neo-vascularization and tumor response to the tyrosine kinase inhibitor cediranib

Human cancer cell lines resistant to EGFR inhibitors acquire an altered expression of VEGFR-1/Flt-1 and become sensitive to ZD6474

Tumor overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126

Sensitivity of NSCLC cell lines bearing wild type and mutated EGFR to the VEGF/EGFR inhibitor ZD6474

Response of murine liver metastasis to the vascular-disrupting agent ZD6126 assessed by susceptibility MRI

Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer

AZD2171, an orally active inhibitor of VEGFR tyrosine kinase activity, reduces polyp burden in a mouse model of intestinal cancer

ZD6474 inhibits human lung cancer bone metastases in a murine model by targeting both the tumor and its vasculature

Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells

Effect of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis and vessel density in murine renal cell carcinoma

The VEGF receptor tyrosine kinase inhibitor ZD6474 significantly reduces intestinal tumor burden in the Min mouse

Resistance of U87 glioblastoma to the vascular targeting agent, ZD6126: Reversal of resistance by NOS inhibitor, L-NNA

Effect of cytotoxic antineoplastic drugs on endothelial cell response in vitro to the vascular-targeting agent ZD6126

ZD6474, an Orally Available Inhibitor of KDR Tyrosine Kinase Activity, Efficiently Blocks Oncogenic RET Kinases

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only